Genkyotex Raises CHF25 Million in Series C Round Extension
03:00 EDT 9 Jul 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Genkyotex, the leading developer of NOX inhibitors to treat
oxygen-radical mediated diseases, announced today the closing of a CHF25
million (USD26 million) extension to its Series C financing. Investors
in the Series C round, i...
Other Sources for this Article
Dr. Ursula Ney
CEO, Genkyotex
Tel: +41 22 880 1025
Mo:
+44 7900 898 708
Email: ursula.ney@genkyotex.com
or
Mike
Sinclair
Halsin Partners
Tel: +44 20 7318 2955
Mo:
+44 7968 022075
Email: msinclair@halsin.com
More From BioPortfolio on "Genkyotex Raises CHF25 Million in Series C Round Extension"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
